? BIOSPECIMEN SERVICES SHARED RESOURCE (BSSR) The mission of the BSSR is to support innovative translational research to advance the prevention, diagnosis, and treatment of cancer through the provision of biospecimens and clinical data.
The Specific Aims are to: 1) collect data and specimens from OSUCCC cancer patients using the IRB-approved Total Cancer Care (TCC) universal consenting and biobanking protocol for future unspecified research; 2) prospectively procure biospecimens for specific IRB-approved protocols; and 3) provide high quality, centralized biorepository services for IRB-approved, grant-funded and large institutional projects in a CAP-accredited biorepository. Over the current grant cycle, the major changes for the BSSR include: a) implementation of TCC across all Disease Specific Research Groups (DSRGs) covering all cancers - TCC now includes 57,256 consented subjects resulting in regular usage of biospecimens and data; and, b) the ORIEN AVATAR program was initiated, providing OSUCCC members with research grade next generation exome sequencing results on tumor and normal tissue with clinical annotation from 3,049 TCC subjects at OSU and 11,500 across ORIEN (the OSUCCC is a major contributor of samples). During the current grant cycle, the BSSR provided key services in support of 122 publications (35 > 10 impact factor), 105 users, and 24 NCI grants, including 1 K01, 1 K12, 2 P01s, 2 P50s, 11 R01s, 4 R21s, 1 U10, 1 UH2, and 1 UM1. Over the next grant cycle, BSSR will contribute to each of the new strategic priorities for the OSUCCC by providing biospecimens and high quality genomic and clinical data as requested by immuno-oncology, translational genomics, cancer engineering and cancer prevention and survivorship investigators. Each area will be supported by the TCC, and given the robust faculty recruitment and regularly increasing patient volumes; there will be an increase in prospective procurement and biobanking as well. Given the robust OSUCCC recruitment and increasing patient volumes, demand for services and new technologies will increase. The BBSR will expand its staff, instrumentation and services before capacity is reached. The annual budget of the BSSR is $2,206,277, yet the CCSG request is $179,168. As such, The BSSR leverages extensive institutional support and seeks only 8.1% support from CCSG funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Poorman, Caroline E; Ethun, Cecilia G; Postlewait, Lauren M et al. (2018) A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Ann Surg Oncol 25:520-527
Stover, Daniel G; Gil Del Alcazar, Carlos R; Brock, Jane et al. (2018) Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 4:10
van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380
Das Ghatak, Piya; Mathew-Steiner, Shomita S; Pandey, Priyanka et al. (2018) A surfactant polymer dressing potentiates antimicrobial efficacy in biofilm disruption. Sci Rep 8:873
Bhattacharya, Mohini; Berends, Evelien T M; Chan, Rita et al. (2018) Staphylococcus aureus biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. Proc Natl Acad Sci U S A 115:7416-7421
Kodigepalli, Karthik M; Li, Minghua; Bonifati, Serena et al. (2018) SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle 17:2564-2576
Woodard, John L; Huntsman, Andrew C; Patel, Pratiq A et al. (2018) Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones. Bioorg Med Chem 26:2354-2364
Miller, Katherine E; Kelly, Benjamin; Fitch, James et al. (2018) Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. Cold Spring Harb Mol Case Stud 4:
Chen, Xiang; Wei, Jia; Li, Chenglong et al. (2018) Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. Int J Oncol 52:571-578
Ghonime, Mohammed G; Jackson, Josh; Shah, Amish et al. (2018) Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol 11:86-93

Showing the most recent 10 out of 2602 publications